“Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026” Report Highlights:
- Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs
- Marketed Cancer Antibody Drug Conjugate: 9 Drugs
- Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026
- Majority of Drug Trials Are For Second Line Therapy Or Greater
- USA Dominates Cancer ADC Clinical Trials Landscape: > 180 Drugs
- Tubulin Modulators Dominates Cancer ADC Trials: > 60 Drugs
- Sales, Market Opportunity, Clinical Trials Graphs: > 100 Graphs
Download Report: https://www.kuickresearch.com/report-global-cancer-antibody-drug-conjugate-market,-price,-dosage-and-clinical-trials-insight-2026.php
Table of Contents
- Introduction to Antibody Drug Conjugates (ADCs)
1.1 Overview
1.2 Historical Development of ADCs
- Evolution of Antibody Drug Conjugates
2.1 Advancements in ADCs
2.1.1 First Generation
2.1.2 Second-Generation
2.1.3 Third Generation
2.2 Components of ADCs
2.2.1 Monoclonal Antibodies (mAbs)
2.2.2 Linkers
2.2.3 Payloads
- Antibody Drug Conjugates – Mechanism of Action
3.1 Antigen – Antibody Interaction
3.2 Release of Payload
3.3 Mechanism of Cytotoxicity
- Need of Antibody Drug Conjugates
- Role of ADCs in Cancer Management
5.1 Breast Cancer
5.2 Leukemia
5.3 Lymphoma
5.4 Other Cancers
- Antibody Drug Conjugate Market Analysis
6.1 Overview
6.2 Current Market Scenario
6.3 ADCs Market Segmentation
6.3.1 Regional Segmentation
6.3.2 Segmentation By Products
- Global – Cancer Antibody Drug Conjugate Market Insights
7.1 US
7.2 Europe
7.2.1 Germany
7.2.2 Belgium
7.2.3 France
7.2.4 United Kingdom
7.3 Japan
7.4 China
7.5 India
7.6 South Korea
- Antibody Drug Conjugates – Availability, Dosage & Price Analysis
8.1 Mylotarg (Gemtuzumab ozogamicin)
8.2 Adcetris (Brentuximab vedotin)
8.3 Kadcyla (Trastuzumab emtansine)
8.4 Besponsa (Inotuzumab ozogamicin)
8.5 Lumoxiti (Moxetumomab pasudotox)
8.6 Polivy (Polatuzumab vedotin)
8.7 Enhertu (Fam-Trastuzumab Deruxtecan-Nxki)
8.8 Padcev (Enfortumab Vedotin)
- Antibody Drug Conjugates – Sales Insight
9.1 Kadcyla
9.2 Adcetris
9.3 Polivy
- Antibody Drug Conjugates – Clinical Pipeline Insight 2020 – 2026
10.1 By Phase
10.2 By Indication
10.3 By Company
10.4 By Patient Segment
10.5 By Country
10.6 By Mechanism of Action
- Global Cancer Drug Conjugates Clinical Pipeline By Company, Indication & Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-0
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
11.10 Preregistration
11.11 Registered
- Marketed Cancer Drug Conjugates Clinical Insight
12.1 Adcetris
12.2 Mylotarg
12.3 Junovan/Mepact
12.4 Kadcyla
12.5 Besponsa
12.6 Zevalin/ Zevamab
12.7 LUMOXITI
12.8 OncoScint CR/OV
12.9 Enhertu
- Global Cancer an Antibody Drug Conjugates Market Dynamics
13.1 Favorable Parameters
13.2 Challenges for Antibody Drug Conjugates Market
- Antibody Drug Conjugates Market – Future Outlook
- Competitive Landscape
15.1 AstraZeneca plc
15.2 Genentech
15.3 Roche
15.4 Takeda Pharmaceuticals
15.5 Pfizer
15.6 Oxford BioTherapeutics
15.7 Heidelberg Pharma
15.8 Synthon
15.9 Mersana Therapeutics
15.10 Progenics Pharmaceuticals
15.11 Astellas Pharma
15.12 Bristol Mayer Squibb
15.13 Seattle Genetics
15.14 Immunogen
15.15 Celldex Therapeutics
Immunogen
Celldex Therapeutics
Contact:
Sussan
sussan@kuickresearch.com
+91-09810410366
